Tags : HFpEF

Pharma

Novartis Reports Results of Entresto (sacubitril/valsartan) in Three P-III PARAGON-HF

Shots: The P-III PARAGON-HF study involves assessing of Entresto vs valsartan in 4,822 HF patients with preserved ejection fraction, resulted in 13% reduction in HF hospitalization and CV death, 15% reduction in total HF hospitalization but narrowly missed the statistical significance, patients with left ventricular ejection fraction ≤57% median showed greater effect The P-IV PROVE-HF […]Read More